Understanding Clinical Trial Phases: From Lab Bench to Approved Treatment

Before the Phases Begin: Preclinical Research

When a research team identifies a compound that might treat a disease, the first tests never involve people. Preclinical research — conducted in laboratory cell cultures and animal models — establishes basic biological plausibility and screens for obvious toxicity. Scientists examine how a compound behaves in living tissue, what dose range might be therapeutic, and whether serious harms are immediately apparent.

Only a small fraction of compounds survive preclinical screening. For those that do, researchers submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) before any human testing begins. Regulatory approval of the IND is a prerequisite — not just a formality — for opening a clinical trial. This gate is one reason the path from discovery to approval is measured in years, not months.

Understanding this early stage matters when evaluating news coverage. A drug described as "showing results in animal studies" is still at the very beginning of an extremely long road. For more on how to interpret that kind of reporting, see how to read a health study headline without being misled.

Phase 1: Is It Safe?

Phase 1 is the first time a treatment is tested in humans, typically in 20 to 100 healthy volunteers, though cancer drug trials often enroll patients with the target disease because the compounds carry significant inherent risk. The central question is safety, not cure.

Researchers incrementally increase the dose across participant groups — a process called dose escalation — watching closely for adverse effects. They also study how the body absorbs, distributes, and eliminates the compound (a field called pharmacokinetics). The goal is to identify the maximum tolerated dose and flag any serious toxicity signals early.

Roughly 70 percent of drugs advance from Phase 1, according to FDA data — making it the stage with the highest pass rate. That figure can create misleading optimism in headlines, since attrition increases sharply in later phases.

Phase 2: Does It Show Promise?

Phase 2 expands testing to 100 to 300 participants who have the condition the treatment is designed to address. Researchers are now asking two questions simultaneously: does the treatment produce measurable biological effects, and does its safety profile hold up in a larger, more diverse group?

Many Phase 2 trials are randomized — participants are assigned by chance to receive either the experimental treatment or a comparison (often a placebo or existing standard of care). This design, discussed at length in our companion piece on observational studies versus randomised controlled trials, reduces the risk that researchers' or participants' expectations will skew the results.

Only about one-third of treatments entering Phase 2 advance to Phase 3. A positive Phase 2 result is newsworthy, but it is appropriately described as preliminary — sample sizes are still too small to establish proof of benefit.

Phase 3: Does It Work at Scale?

Phase 3 trials are the pivotal studies that regulatory decisions hinge on. They typically enroll 1,000 to 10,000 or more participants across multiple sites, sometimes internationally. The trial is usually randomized and double-blind — neither participants nor the researchers assessing outcomes know who received the treatment — to eliminate conscious and unconscious bias.

Phase 3 addresses effectiveness at scale, compares the treatment against the current standard of care, and is powered statistically to detect meaningful differences between groups. Rare adverse events that Phase 1 and 2 studies were too small to catch can surface here.

Because Phase 3 trials are the most rigorous pre-approval evidence, a successful result carries substantially more weight than earlier phases. Even so, readers should note the specific population enrolled, the outcome measured, and the size of the benefit — details that health headlines frequently compress or omit. For a practical guide on spotting those gaps, see common errors in reporting medical research.

Regulatory Review and Phase 4

After a successful Phase 3 trial, the sponsor submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA. Reviewers examine the complete dataset — not just published papers — including raw trial data, manufacturing processes, and proposed labeling. This review typically takes six to twelve months under a standard pathway, though priority and accelerated designations can shorten that window.

Approval is not the final chapter. Phase 4, often called post-market surveillance, begins once a treatment reaches patients. Because even large Phase 3 trials cannot detect side effects occurring in fewer than 1 in 1,000 people, ongoing safety monitoring is essential. Regulatory agencies can require label changes, restrict use, or withdraw approval based on Phase 4 findings.

Keeping this framework in mind helps contextualize any health development you encounter — whether it concerns a novel drug, a reformulated vaccine, or an emerging wellness treatment. If you want to apply similar critical thinking to wellness trends more broadly, evaluating a new wellness trend before committing to it offers a useful follow-up framework.

This article is for general informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for guidance specific to your health situation.